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Summary: The kinetics and efficiency of the interaction between placental alkaline phosphatase and a
monoclonal antibody (laboratory number 327) were determined by immunoassay using microtitre plates or
magnetic beads. While only up to 45% of placental alkaline phosphatase was bound to microwells precoated
with this antibody, even after prolonged incubation, no less than 60% and 100% binding were reached using
magnetic beads after 1 and 3 h incubations, respectively.
High-molecular-mass placental alkaline phosphatase and complexed placental alkaline phosphatase forms
were also completely bound to magnetic beads in the presence of deoxycholate (up to 9 g/1 for serum samples).
The assay sensitivity was improved up to 4-fold. In addition, 100% binding of the antigen was achieved
during simultaneous incubation of magnetic beads, monoclonal antibody (125 μg/l), and placental alkaline
phosphatase. This one-step enzymatic assay, based on magnetic beads, is an attractive alternative to the
classic assay performed in microtitre plates, enabling rapid, precise, and sensitive antigen detection, and only
necessitating a minimum of laboratory equipment.
Introduction , ^ ι ,very early treatment 01 adult respiratory distress syn-
Placental and germ cell alkaline phosphatase1) are drome is currently hindered due to the lack of sensitive
useful tumour markers for ovarian or seminoma can- markers (4). Based on a prospective study, it was
cer (1). Additionally, due to the near monopoly of the concluded that serum placental alkaline phosphatase
lung in expressing placental alkaline phosphatase, this elevations almost invariably preceded adult respira-
isoenzyme also shows an interesting potential as a tory distress syndrome, suggesting that frequent pla-
marker for injury to the alveolar-capillary barrier, cental alkaline phosphatase determinations could in-
Placental alkaline phosphatase activity has been de- crease the sensitivity for detection of developing adult
tected in some epithelial cells of the respiratory bron- respiratory distress syndrome. The observation that
chioli and in type I pneumocytes. In addition, a sub- adult respiratory distress syndrome did not develop
stantial amount of the enzyme is liberated from the in subjects maintaining normal serum placental al-
basal cell surface of the latter cells into the underlying kaline phosphatase levels throughout the first 48 h
membrane (2). Indeed, elevated placental alkaline after admission (3) was particularly relevant.
phosphatase serum levels have been found in several τ , , Λ , . . r ι * ι, . . . , . ι . · ι ι In order to develop and optimize a fast placentalconditions involving acute lung iniury such as the „ ,. , , „ «, . . A ,. j /ox τ» · alkaline phosphatase assay to measure small fluctua-adult respiratory distress syndrome (3). Preventive or . , , „ ,. , ,tions in serum placental alkaline phosphatase levels,
a magnetic enzyme activity immunoassay, based on
') Enzyme: Alkaline phosphatase (EC 3.1.3.1) specific isoenzyme capture followed by measurement
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of retained enzyme activity, was compared with the
classic version of this assay which was performed in
microtitre plates. We presently describe this immu-
nomagnetic assay, which is based on an anti-placental
alkaline phosphatase monoclonal antibody (labora-
tory number 327 (5)). Because of improved diffusion
and larger sample volumes, this assay enables a rapid
(within 2 h), accurate, and precise determination of
low serum placental alkaline phosphatase levels.
Materials and Methods
Chemicals and supplies
Rabbit anti-mouse IgG was supplied by Dakopatts (Glostrup,
Denmark). Deoxycholate and /?-nitrophenyl phosphate were
from Sigma Chemical Co. (St. Louis, MO). Ninety-six-well
microtitre plates were from Nunc (Roskilde, Denmark). The
magnetic beads (Dynabeads M-450; 4.5 μηι diameter) were
supplied by Dynal (Skoyen, Norway). These Dynabeads are
uniform magnetic polystyrene beads with 5 μg of affinity pur-
ified sheep-anti-mouse IgGl (Fc) covalently bound to the sur-
face of one mg beads; they are sold as a suspension containing
approximately 420 χ ΙΟ9 beads (30 g) per litre. Sephacryl S-
300 was purchased from Pharmacia Fine Chemicals (Uppsala,
Sweden). The EAR400 multi-well reader was from SLT-labin-
struments (Groding, Austria). All other regular reagents were
of pro analysis quality from Merck (Darmstadt, Germany).
Placental alkaline phosphatase isoforms
Placental alkaline phosphatase was extracted from a fresh pla-
centa and gel filtration on a 1.6 χ 77 cm column of Sephacryl
S-300 was performed as described (5), separating placental
alkaline phosphatase into a dimeric enzyme (Mr = 130000)
and a high-molecular-mass placental alkaline phosphatase-con-
taining peak, eluting just behind the void volume of the column
(Afr 106). After affinity chromatography, anion exchange and
size-exclusion HPLC, the specific activity of placental alkaline
phosphatase (> 95% pure) was 250 U/mg (5).
Enzyme activity immunoassay in microti tre wells
Placental alkaline phosphatase was assayed as described pre-
viously (6), using the anti-placental alkaline phosphatase mono-
clonal antibody 327 (5). Placental alkaline phosphatase samples
(0.25 U/l, 200 μΐ) were incubated at 37 °C for 3 h, or as specified,
and bound enzyme was visualised with 10 mmol/1 /?-nitrophenyl
phosphate in N-ethylaminoethanol HC1 buffer (20 g/l, pH 10.2).
The fraction of binding was calculated by comparison with the
activity of known standards.
Enzyme activity immunoassay with immunomag-
netic beads
In the two-step assay, sheep anti-mouse IgGl (Fc) coated mag-
netic beads were preloaded with antibody 327 by incubating
12 μΐ of the bead suspension in 120 μΐ of antibody solution (0
to 16 mg/1), for 5 h at 37 °C, under continuous stirring. After
magnetic phase separation, the beads were washed 3 times in
1 ml of phosphate buffered saline, containing 0.5 ml of Tween-
80 per litre, then resuspended in 120 μΐ of blocking solution.
These preloaded immune-beads (50 μΐ) were added to one ml
placental alkaline phosphatase samples (0.25 U/l) and incubated
at 37 °C for 3 h under gentle stirring. After magnetic phase
separation, the supernatants were removed and the unbound
placental alkaline phosphatase was measured. Bound placental
alkaline phosphatase activity was visualized by addition of 200
μΐ of the buffered substrate solution to the beads. Staining was
arrested after 45 min by the addition of 30 μΐ of a concentrated
NaOH (5mol/l) solution. Then, 200 μΐ of supernatants or
standards were transferred to a 96-well microtitre plate to
measure the absorbance at 405 nm in an EAR 400 multi-well
reader, followed by calculation of the percentages of bound
placental alkaline phosphatase.
Alternatively, in the one-step assay, 5 μΐ of sheep anti-mouse
IgGl (Fc)-coated beads were adjusted to 25 μΐ with blocking
solution and incubated simultaneously with 25 μΐ of antibody
solution (0 to 16 mg/1, or at 125 μg/l, as specified) and a
placental alkaline phosphatase-containing sample (0.25 U/l,
1 ml). Incubations were performed at 37 °C under continuous
gentle stirring for various time intervals. The magnetic phase
separation and determination of placental alkaline phosphatase
binding was performed as described above.
The accuracy of the placental alkaline phosphatase determi-
nation in this simultaneous incubation protocol was tested for
a progressively diluted series of placental alkaline phosphatase
samples (1 to 0.001 U/l; l ml), choosing a fixed antibody con-
centration (125 μg/l), and two different incubation times, i.e.
1 or 3 h, in combination with two different colour development
times of 1 and 3 h, respectively. Binding efficiencies of high-
and low-molecular-mass placental alkaline phosphatase were
studied in a similar way.
Recovery analysis in serum
The magnetic bead immunoassay was performed on fresh sera,
containing 0 to 2.5 U/l placental alkaline phosphatase which
were supplemented with 250 mU of placental alkaline phos-
phatase per litre in the presence or absence of deoxycholate
(9 g/1). The recovery was expressed using the following formula:
(A4Q5 nm (supplemented serum) — A^s nm (non-supplemented serum)) χ 100
(placental alkaline phosphatase supplement)
Results
Binding of placental alkaline phosphatase by
antibody 327 insolubilised on magnetic beads
Results from the preloading of 5 μΐ of the sheep anti-
mouse IgGl (Fc)-coated beads (i.e. 2.1 χ ΙΟ6 beads,
coated with 750 ng sheep anti-mouse IgGl (Fc)) with
increasing concentrations of the anti-placental alka-
line phosphatase monoclonal antibody 327, and sub-
sequent incubation with placental alkaline phospha-
tase samples for 3 h at 37 °C, indicated that 100% of
the antigen could be bound to the solid phase when
the antibody concentration was above 150 ng anti-
body/120 μΐ during preloading (fig. 1). When magnetic
beads, antibody, and placental alkaline phosphatase
sample were incubated simultaneously, the percentage
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of placental alkaline phosphatase bound to the solid
phase rose with increasing antibody concentrations.
Complete antigen binding was observed at antibody
concentrations of 125 μg/l, corresponding to surface
densities of 0.036 pg antibody 327 per bead, i. e. 56
ng/cm2. At antibody concentrations exceeding 500
μg/l, increasing concentrations of free antibodies com-
peted for placental alkaline phosphatase-binding with
the bound antibodies, explaining the descending limb
of figure 1. Complementary measurements of un-
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Fig. 1. Efficiency of placental alkaline phosphatase binding by
increasing concentrations of monoclonal antibody 327
in a magnetic enzyme activity immunoassay. Placental
alkaline phosphatase (0.25 U/l; l ml) was incubated with
gentle stirring for 3 h at 37 °C with increasing concen-
trations of antibody 327 (0 to 16 mg/l), either attached
on the magnetic sheep anti-mouse IgGl (Fc)-coated
beads beforehand, or incubated simultaneously with the
antigen and the beads. The assays were continued
(washing and staining) as described in Materials and
Methods.
o, antibody concentrations during preloading of the
sheep anti-mouse IgGl (Fc)-coated magnetic beads;
·, antibody concentrations during the one-step mag-
netic bead immunoassay.
Kinetics of placental alkaline phosphatase
binding in the magnetic bead assay
During the simultaneous incubation with beads (5 μΐ)
and antibody (125 μg/l), the binding of placental
alkaline phosphatase displayed first-order kinetics up
to 1 h. An incubation time of 3 h was required to
achieve complete antigen binding (fig. 2). During the
immunoassay in microtitre wells, a much slower bind-
ing kinetic was observed, associated with a maximal












Fig. 2. Kinetics of placental alkaline phosphatase binding by
antibody 327 in the EAIA performed on sheep anti-
mouse coated magnetic beads or in micro titre plates. In
the magnetic bead assay, a placental alkaline phospha-
tase-containing sample (0.25 U/l; l ml) was incubated
for several time intervals with 25 μΐ antibody (final
concentration 125 μg/l) and 5 μΐ immunobead suspen-
sion, adjusted to 25 μΐ beforehand.
In the classic immunoassay, 200 μΐ of the same placental
alkaline phosphatase sample was incubated for different
time intervals in microwells, preloaded with an excess
of antibody.
Both assays were continued as described in Materials
and Methods.
·, magnetic bead enzyme activity immunoassay;
O, classic enzyme activity immunoassay.
Standard curves, sensitivity and precision of
the magnetic bead enzyme activity immuno-
assay
In the simultaneous incubation protocol, the fraction
of bound placental alkaline phosphatase was con-
stant, even for low placental alkaline phosphatase
concentrations, i.e. about 60 and 100% for the short
and prolonged assay procedures, respectively. The
lower detection limit (defined as the amount of pla-
cental alkaline phosphatase corresponding to the up-
per limit of a 99% confidence interval of zero) cor-
responded to 0.006 U/l in the extended protocol (3 h
incubation, 3 h colour development), whereas in the
short assay (l h incubation, l h colour development),
it was 0.009 U/l. By contrast, the assay performed in
microtitre plates showed a lower detection limit of
0.022 U/l placental alkaline phosphatase (3 h incu-
bation, 3 h colour development).
Precision and accuracy of placental alkaline
phosphatase measurement in serum using the
magnetic bead enzyme activity immunoassay
This assay was satisfactory in terms of precision and
accuracy. Analysis of two samples containing different
amounts of placental alkaline phosphatase gave the
following within-assay variation (n = 8 determina-
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tions each): 1.4 + 0.06 U/l (CV 4.0%) and 12.95
± 0.44 μ§/1 (CV 3.4%). The between-assay variation
calculated for the first sample on 4 consecutive days
was 1.35 ± 0.06 μ§/1 (CV 4.2%). Using the magnetic
immunoassay on fresh sera (containing 0 to 2.5 U/l
placental alkaline phosphatase) which were supple-
mented with a known amount of placental alkaline
phosphatase, only very low recoveries were obtained,
varying from 4.3% to 57.0%. In view of the results
obtained with deoxycholate in the microplate assay
(4), this detergent (9 g/1 final concentration) was also
added in the present magnetic bead assay; recovery
of placental alkaline phosphatase (95.7 ± 3.4%,
η = 10) was complete, allowing accurate and precise
placental alkaline phosphatase measurements in hu-
man serum samples.
Influence of antigen size on binding effi-
ciency
The need for detergent inclusion during antigen in-
cubation was particularly evident for the detection of
high-molecular-mass placental alkaline phosphatase
in microtitre plates. Only 11% of these placental
alkaline phosphatase forms could be bound in the
absence of deoxycholate, whereas 43% of dimeric
placental alkaline phosphatase was bound. When de-
oxycholate concentrations were increased to 1 g/1,
high- and low-molecular-mass placental alkaline
















Fig. 3. Efficiency of binding of high-molecular-mass placental
alkaline phosphatase by increasing concentrations of
antibody 327, in the presence or absence of deoxycho-
late. High-molecular-mass placental alkaline phospha-
tase (0.25 U/l; l ml) and increasing concentrations of
antibody 327 (0.002 to 16 mg/l) were incubated simul-
taneously for 3 h at 37 °C with 5 μΐ of a suspension of
magnetic sheep anti-mouse IgGl (Fc)-coated beads,
both in the presence or absence of deoxycholate (1 g/1).




ing to the magnetic assay did not improve the binding
of the high-molecular-mass placental alkaline phos-
phatase (< 15%), unless deoxycholate was added.
The binding efficiency then returned to 100% at the
optimal antibody concentration of 125 μg/l (fig. 3).
Discussion
The enzyme activity immunoassay principle, in which
the enzyme activity of placental alkaline phosphatase
is measured at the detection step (7), was developed
for testing hybridoma cultures secreting anti-placental
alkaline phosphatase monoclonal antibodies (8) and
for the screening of placental alkaline phosphatase
positivity in the serum of cancer patients (1). The
present comparison of microplates and magnetic
beads for use in an immunoassay, based on a specific
anti-placental alkaline phosphatase monoclonal an-
tibody, revealed a substantial increase, up to 100%,
in the effectiveness of placental alkaline phosphatase
binding in the assay, using magnetic beads. In addi-
tion to the advantage of using larger sample volumes
(translated into higher sensitivities) and the easy phase
separation, the simultaneous incubation of antigen,
antibody, and magnetic beads made this an attractive
assay. When the antibody concentration was raised
in the one-step configuration, a plateau was reached
between 0.1 and 0.5 mg/l, i.e. the ascending (antigen
binding) and descending (competition) limbs of the
curve were clearly separated. The high binding per-
centages obtained may be explained by a better ori-
entation of antibody 327 (IgGl) when bound to the
solid-phase, because the antibodies react exclusively
with the Fc fragment of mouse IgGl immunoglobu-
lins, in contrast to the more random orientation of
antibody 327 when bound to rabbit anti-mouse IgG-
coated micro wells. Furthermore, by gently stirring the
beads homogeneously in the sample fluid, diffusional
restrictions were reduced, leading to a more effective
contact between the antibody and the antigen mole-
cules than during incubations in microtitre wells. Fi-
nally, while total covered areas in both assay types
were comparable, the amount of monoclonal anti-
body calculated per unit surface area was twice as
high for the magnetic beads than for the micro wells.
The linearity of the standard curves indicated that the
reaction rates were proportional to the amounts of
placental alkaline phosphatase present, even for low
concentrations of placental alkaline phosphatase. Pla-
cental alkaline phosphatase levels as low as 0.006 U/l
could be accurately measured during the longer ver-
sion of the protocol (3 h incubation, 3 h staining).
When the total assay time was reduced to 2h, the
detection limit was reduced to 60%.
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Although high binding efficiencies were observed for
dimeric placental alkaline phosphatase, the recovery
of high-molecular-mass placental alkaline phospha-
tase on the immunomagnetic beads was as poor as in
the assay performed in microplates. However, upon
dissociation of these placental alkaline phosphatase
forms by deoxycholate, the magnetic immunoassay
accurately reflected the total placental alkaline phos-
phatase levels. When measuring placental alkaline
phosphatase levels in serum, even higher concentra-
tions of deoxycholate were required due to interac-
tions with other serum components, similarly to those
seen in the enzyme activity immunoassay performed
in microtitre plates (5).
When using a previously described solid-phase im-
munoassay for placental alkaline phosphatase based
on small (3.3 μιη) monodisperse polymer particles
(non-magnetic) (9), complete placental alkaline phos-
phatase binding was achieved after only 10 min of
incubation, probably linked to the use of a higher
affinity antibody. Nevertheless, the magnetic bead
assay has the advantage of being a simple, one-step
procedure, and magnetic separation obviates the need
for centrifugation. The availability of a properly
graded colour scale would also eliminate the need for
spectrophotometric reading. The magnetic bead en-
zyme activity immunoassay for placental alkaline
phosphatase thus proposed meets all the criteria for
a bedside placental alkaline phosphatase test during
the follow-up of patients at risk of developing adult
respiratory distress syndrome: it is a quick and simple
method, without compromising assay sensitivity, ac-
curacy, or precision.
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